TC Biopharm (Holdings) PLC kwuputara na ọ natala nnabata MHRA na Kọmitii Ethics Committee iji malite nnwale ụlọ ọgwụ gamma-delta T cell nke OmnImmune® maka ọgwụgwọ nke ọrịa leukemia na-egbu egbu Myeloid (AML).
OmnImmune® usoro ọgwụgwọ cell na-adịghị agbanwe agbanwe nke nwere sel gamma delta T arụgoro na gbasaa enwetalarị aha ọgwụ mgbei maka ọgwụgwọ ndị ọrịa na-arịa ọrịa kansa ọbara na ụmị ọkpụkpụ. Ọnwụnwa nke 2/3 ga-amalite ndebanye aha na ọkara mbụ nke 2022 na UK na mgbasawanye na US na-esote obere oge ka nke ahụ gasịrị.
"Obi dị anyị ụtọ nke ukwuu ịnata nnabata MHRA na ụkpụrụ omume nyocha, nke na-egosi nzọụkwụ ikpeazụ na nrubeisi protocol anyị wee malite site na usoro nnwale ụlọ ọgwụ nke ọgwụgwọ AML nke ụlọ anyị," Bryan Kobel, CEO nke TC BioPharm kwuru. "N'ikiri ụkwụ nke ikwuwapụta Dọkịta Ọgwụ Ọgwụ Orphan anyị site na FDA, anyị egosipụtala ugbu a ikike anyị nwere ịme usoro yiri nke ahụ maka ule ụlọ ọgwụ na US na UK / EU. Nsonaazụ dị mma nke OmnImmune® gosipụtara na Phase 1b/2a nnwale ụlọ ọgwụ na-agba ume ma na-akwado nkwenye anyị na ikike ya dị ka ọgwụgwọ dị irè maka ọrịa kansa ọbara Myeloid siri ike.
IHE Ị GA-Ewepụ na edemede a:
- OmnImmune® usoro ọgwụgwọ cell na-adịghị agbanwe agbanwe nke nwere sel gamma delta T arụgoro na gbasaa enwetalarị aha ọgwụ mgbei maka ọgwụgwọ ndị ọrịa na-arịa ọrịa kansa ọbara na ụmị ọkpụkpụ.
- Nsonaazụ dị mma nke OmnImmune® gosipụtara na Phase 1b/2a ule ụlọ ọgwụ na-agba ume ma na-akwado nkwenye anyị na ike ya dị ka ọgwụgwọ dị irè maka ọrịa kansa ọbara Myeloid dị mma.
- TC Biopharm (Holdings) PLC kwuputara na ọ natala nnabata MHRA na Kọmitii Ethics Committee iji malite nnwale ụlọ ọgwụ gamma-delta T cell nke OmnImmune® maka ọgwụgwọ nke ọrịa leukemia na-egbu egbu Myeloid (AML).
